NCT04617054Phase 2Terminated

Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-06Actual
Enrollment · participants14Actual
Source updated2026-01-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Best overall response (BOR). After: Measure: Objective response rate (ORR).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 40 participants (planned). After: 14 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 Apr 2024. After: 6 Dec 2024.

Recruitment status changed

Before: Recruiting. After: Terminated.

Check registry source